NewLimit raises $435M to treat cellular aging as disease

A $3.1B valuation for NewLimit signals that epigenetic reprogramming and aging biology have moved from speculative longevity research into large-scale company building

NewLimit just closed a $435M Series C at a $3.1B valuation. We backed them early, when most people thought treating cellular aging like a disease was a decade away at minimum. @jacobkimmel and @brian_armstrong saw it differently. That

Ranked #16 on backlist 2026-06-04 (04 Jun 2026 UTC) · by @maxime_bucaille (Maxime Bucaille) · view on X ↗

How it ranks: Backlist reads my Twitter/X timeline, scores every tweet for substance with an LLM rubric (not engagement), and publishes the daily top picks with a one-line takeaway. Curated by Surya Dantuluri.